Connection

JOSEPH JANKOVIC to Mice

This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Mice.
Connection Strength

0.160
  1. Genetic mouse models of essential tremor: are they essential? J Clin Invest. 2005 Mar; 115(3):584-6.
    View in: PubMed
    Score: 0.019
  2. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
    View in: PubMed
    Score: 0.012
  3. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.011
  4. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012 Sep; 11(6):768-73.
    View in: PubMed
    Score: 0.008
  5. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012 Jan 26; 1(1):2-12.
    View in: PubMed
    Score: 0.007
  6. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
    View in: PubMed
    Score: 0.007
  7. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010 Oct; 115(1):188-99.
    View in: PubMed
    Score: 0.007
  8. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010 Feb; 37(2):307-13.
    View in: PubMed
    Score: 0.006
  9. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
    View in: PubMed
    Score: 0.006
  10. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.006
  11. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008 Oct; 32(1):16-25.
    View in: PubMed
    Score: 0.006
  12. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008 Jul 30; 1222:222-9.
    View in: PubMed
    Score: 0.006
  13. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008 Jun; 105(5):1970-8.
    View in: PubMed
    Score: 0.006
  14. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007 Dec; 21(14):3835-44.
    View in: PubMed
    Score: 0.006
  15. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
    View in: PubMed
    Score: 0.005
  16. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
    View in: PubMed
    Score: 0.005
  17. Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. FASEB J. 2005 Sep; 19(11):1441-50.
    View in: PubMed
    Score: 0.005
  18. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005 Jan; 191(1):154-62.
    View in: PubMed
    Score: 0.005
  19. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004 Mar-Apr; 27(2):63-73.
    View in: PubMed
    Score: 0.004
  20. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003 Jan 17; 72(9):1073-83.
    View in: PubMed
    Score: 0.004
  21. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
    View in: PubMed
    Score: 0.004
  22. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000 Mar 10; 281(2-3):167-70.
    View in: PubMed
    Score: 0.003
  23. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999 Nov; 73(5):2218-21.
    View in: PubMed
    Score: 0.003
  24. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999 Oct; 159(2):451-8.
    View in: PubMed
    Score: 0.003
  25. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
    View in: PubMed
    Score: 0.003
  26. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.